Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail patients with advanced CRC. | First-line single-agent regorafenib in frail patients with metastatic colorectal cancer A pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours TTD